J&J Pledges $500m To Eliminate HIV and TB
A HIV vaccine is 'ultimate goal'
Executive Summary
The healthcare giant is investing heavily into partnerships designed to beat the two infectious diseases.
You may also be interested in...
J&J To Build Capacity, Widen Access To Bedaquiline In India
J&J ties up with agencies, Indian government to build capacity and widen access to Sirturo for TB patients.
Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions
US FDA's approval of the TB Alliance's pretomanid regimen for highly treatment-resistant tuberculosis comes with an LPAD designation and advisory committee-requested language to limit use.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.